HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

GENFLEET-B

32.260

-1.240-3.70%

Volume:1.08M

Turnover:35.02M

Market Cap:11.94B

PE:-4.60

High:34.240

Open:32.980

Low:31.040

Close:33.500

52wk High:52.900

52wk Low:19.600

Shares:370.00M

HK Float Shares:338.00M

Volume Ratio:0.97

T/O Rate:0.32%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-7.009

ROE:--

ROA:-12.49%

PB:5.70

PE(LYR):-4.60

PS:79.35

Loading ...

Overview Company News Filings

GENFLEET-B Receives "Buy" Rating and HK$55.63 Target Price in Initiation Coverage by Guojin Securities

Stock Track | Genfleet Therapeutics-B Soars 5.48% Intraday on Breakthrough Therapy Designation for KRAS G12D Inhibitor

GENFLEET-B Shares Surge Over 5% in Morning Session on Second Breakthrough Therapy Designation for GFH375

BRIEF-Genfleet Therapeutics (Shanghai) Says GFH375 Granted Breakthrough Therapy Designation By China's NMPA

GENFLEET-B's GFH375 Granted Second Breakthrough Therapy Designation

GenFleet says China grants breakthrough designation for GFH375 in metastatic pancreatic cancer

Genfleet Therapeutics (Shanghai) Inc - Gfh375 Granted Breakthrough Therapy Designation by China's National Medical Products Administration

THOMSON REUTERS

3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 46.6%

Simply Wall St.

Wellington Management Increases Stake in GENFLEET-B by Approximately 318,247 Shares at Average Price of HK$30.88

GenFleet Therapeutics SEHK 2595 Deepens Losses As Revenue Growth Tests Bullish Narratives

Simply Wall St.

CLSA Raises Target Price for GENFLEET-B to HK$61.9, Keeps Outperform Rating

Stock Track | GENFLEET-B Soars 5.34% Intraday as Key Drug Added to China's National Reimbursement List

BRIEF-Genfleet Therapeutics (Shanghai) Posts FY Loss RMB1.79 BLN

GENFLEET-B Announces Appointment of Huang Meifeng as Co-Company Secretary

GENFLEET-B Reports Annual Loss Widening to 17.95 Billion Yuan

GenFleet Therapeutics FY 2025: Revenue Climbs 24% While Fair-Value Charges Deepen Net Loss; Cash Reserves Surpass RMB 2.07 Billion

Bulletin Express

GenFleet Therapeutics Updates Audit Committee Charter to Strengthen Governance Framework

Bulletin Express

Genfleet Therapeutics (Shanghai) Inc - FY Loss RMB1.79 Bln

THOMSON REUTERS

GenFleet FY2025 net loss widens to RMB 1.79 billion as revenue rises 24.41% to RMB 130 million

Genfleet KRAS G12C inhibitor fulzerasib added to China’s national drug reimbursement list

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/02595/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02595","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"GENFLEET-B","latestPrice":32.26,"timestamp":1779782902006,"preClose":33.5,"halted":0,"volume":1083955,"delay":0,"changeRate":-0.03701492537313439,"floatShares":338000000,"shares":370000000,"eps":-7.009063866468146,"marketStatus":"Not Yet Opened","change":-1.24,"latestTime":"05-26 16:08:22","open":32.98,"high":34.24,"low":31.04,"amount":35016880,"amplitude":0.095522,"askPrice":32.26,"askSize":200,"bidPrice":32.14,"bidSize":4200,"shortable":3,"etf":0,"ttmEps":-6.193841611159001,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779845400000},"marketStatusCode":0,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":33.5,"openAndCloseTimeList":[[1779759000000,1779768000000],[1779771600000,1779782400000]],"volumeRatio":0.967063,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","floatShares":338000000,"roa":"-12.49%","roe":"--","lyrEps":-7.009064,"volumeRatio":0.967063,"shares":370000000,"dividePrice":0,"high":34.24,"amplitude":0.095522,"preClose":33.5,"low":31.04,"week52Low":19.6,"pbRate":"5.70","psRate":"79.35","week52High":52.9,"institutionHeld":0,"latestPrice":32.26,"committee":0.909091,"eps":-7.009063866468146,"divideRate":0,"volume":1083955,"delay":0,"ttmEps":-6.193841611159001,"open":32.98,"prevYearClose":23.78,"prevWeekClose":33.5,"prevMonthClose":43.14,"prevQuarterClose":33.42,"fiveDayClose":34.44,"twentyDayClose":49.46,"sixtyDayClose":28.92},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02595\",params:#limit:5,,,undefined,":[{"date":"2026-03-24","symbol":"02595","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774315800000,"name":null,"time":"","dateTimestamp":1774281600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02595\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02595\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":3,"updateTime":1776268800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02595\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02595","date":"2026-05-22","current":-5.205709,"percent":0.919753,"low":-19.62221,"twenty":-11.098455,"median":-10.138144,"eighty":-8.800358,"high":-5.69787,"avg":-10.419693,"sd":2.620978,"marketCap":12407282105},"quantilePoints":[{"date":"2025-09-19","current":-19.62221,"twenty":-19.62221,"median":-19.62221,"eighty":-19.62221,"marketCap":14538840523},{"date":"2025-09-26","current":-17.850791,"twenty":-18.989349,"median":-18.569255,"eighty":-18.336187,"marketCap":13192012066},{"date":"2025-10-03","current":-19.06699,"twenty":-19.162092,"median":-18.845312,"eighty":-18.417026,"marketCap":14124431767},{"date":"2025-10-10","current":-11.809112,"twenty":-19.045684,"median":-18.645404,"eighty":-16.087956,"marketCap":11948785798},{"date":"2025-10-17","current":-10.861917,"twenty":-19.006201,"median":-18.336187,"eighty":-11.374297,"marketCap":10981832034},{"date":"2025-10-24","current":-9.567304,"twenty":-18.816504,"median":-12.899451,"eighty":-10.554523,"marketCap":9676444452},{"date":"2025-10-31","current":-9.989391,"twenty":-18.681528,"median":-11.762498,"eighty":-10.081819,"marketCap":10118416331},{"date":"2025-11-07","current":-9.878556,"twenty":-18.646705,"median":-10.725216,"eighty":-9.89625,"marketCap":9999899010},{"date":"2025-11-14","current":-11.674836,"twenty":-18.558233,"median":-10.712517,"eighty":-9.936062,"marketCap":11851732160},{"date":"2025-11-21","current":-10.329745,"twenty":-18.396816,"median":-10.725216,"eighty":-10.005136,"marketCap":10481375629},{"date":"2025-11-28","current":-10.423287,"twenty":-18.142029,"median":-10.678396,"eighty":-10.044836,"marketCap":10614707615},{"date":"2025-12-05","current":-10.100425,"twenty":-16.087956,"median":-10.631034,"eighty":-10.044836,"marketCap":10303599646},{"date":"2025-12-12","current":-10.212238,"twenty":-13.008301,"median":-10.584309,"eighty":-10.020393,"marketCap":10436931633},{"date":"2025-12-19","current":-9.790532,"twenty":-12.136764,"median":-10.450758,"eighty":-9.957409,"marketCap":10029528340},{"date":"2025-12-24","current":-8.945585,"twenty":-11.809112,"median":-10.416014,"eighty":-9.900509,"marketCap":9192499756},{"date":"2026-01-02","current":-8.020182,"twenty":-11.73453,"median":-10.320373,"eighty":-9.861601,"marketCap":8273990514},{"date":"2026-01-09","current":-11.588563,"twenty":-11.683046,"median":-10.309663,"eighty":-9.776189,"marketCap":11985064146},{"date":"2026-01-16","current":-11.693807,"twenty":-11.67863,"median":-10.369243,"eighty":-9.793132,"marketCap":12133210798},{"date":"2026-01-23","current":-10.361602,"twenty":-11.605818,"median":-10.329745,"eighty":-9.783265,"marketCap":10740632270},{"date":"2026-01-30","current":-10.919089,"twenty":-11.483053,"median":-10.385171,"eighty":-9.793132,"marketCap":11370255541},{"date":"2026-02-06","current":-11.146899,"twenty":-11.598147,"median":-10.450758,"eighty":-9.8258,"marketCap":11636919514},{"date":"2026-02-13","current":-10.659945,"twenty":-11.483053,"median":-10.58187,"eighty":-9.869606,"marketCap":11192479558},{"date":"2026-02-20","current":-10.145441,"twenty":-11.446311,"median":-10.573435,"eighty":-9.881527,"marketCap":10636929613},{"date":"2026-02-27","current":-9.574146,"twenty":-11.38719,"median":-10.509847,"eighty":-9.836956,"marketCap":10148045662},{"date":"2026-03-06","current":-8.841756,"twenty":-11.29428,"median":-10.416014,"eighty":-9.744297,"marketCap":9296202413},{"date":"2026-03-13","current":-10.316011,"twenty":-11.38719,"median":-10.450758,"eighty":-9.761464,"marketCap":10896186254},{"date":"2026-03-20","current":-10.186272,"twenty":-11.29428,"median":-10.385171,"eighty":-9.744297,"marketCap":10718410272},{"date":"2026-03-27","current":-5.945762,"twenty":-11.270982,"median":-10.329745,"eighty":-9.723416,"marketCap":12081359470},{"date":"2026-04-02","current":-6.621163,"twenty":-11.205287,"median":-10.312136,"eighty":-9.574146,"marketCap":13518381995},{"date":"2026-04-10","current":-7.067323,"twenty":-11.18954,"median":-10.310332,"eighty":-9.547859,"marketCap":14540593893},{"date":"2026-04-17","current":-8.194366,"twenty":-11.170082,"median":-10.271344,"eighty":-9.114302,"marketCap":16866496330},{"date":"2026-04-24","current":-11.736244,"twenty":-11.170082,"median":-10.248784,"eighty":-8.950161,"marketCap":18318333519},{"date":"2026-04-30","current":-10.233962,"twenty":-11.173069,"median":-10.230093,"eighty":-8.995356,"marketCap":15977616418},{"date":"2026-05-08","current":-9.881779,"twenty":-11.158327,"median":-10.186272,"eighty":-9.095725,"marketCap":15481325134},{"date":"2026-05-15","current":-8.422278,"twenty":-11.148553,"median":-10.161068,"eighty":-8.948635,"marketCap":13229496023},{"date":"2026-05-22","current":-7.916926,"twenty":-11.098455,"median":-10.138144,"eighty":-8.800358,"marketCap":12407282105}],"updateTime":1779792921856},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02595\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1111141151","title":"GENFLEET-B Receives \"Buy\" Rating and HK$55.63 Target Price in Initiation Coverage by Guojin Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=1111141151","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111141151?lang=en_us&edition=fundamental","pubTime":"2026-04-15 15:14","pubTimestamp":1776237274,"startTime":"0","endTime":"0","summary":"Guojin Securities has initiated coverage on GENFLEET-B (02595) with a \"Buy\" rating. The firm projects the company's sales revenue for 2026, 2027, and 2028 to be RMB 146 million, RMB 160 million, and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1574","09939","EWH","159938","BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194083813","title":"Stock Track | Genfleet Therapeutics-B Soars 5.48% Intraday on Breakthrough Therapy Designation for KRAS G12D Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=1194083813","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194083813?lang=en_us&edition=fundamental","pubTime":"2026-04-15 09:39","pubTimestamp":1776217187,"startTime":"0","endTime":"0","summary":"Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.48% during intraday trading on Wednesday, extending its recent positive momentum.The surge follows the company's announcement that its...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164883301","title":"GENFLEET-B Shares Surge Over 5% in Morning Session on Second Breakthrough Therapy Designation for GFH375","url":"https://stock-news.laohu8.com/highlight/detail?id=1164883301","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164883301?lang=en_us&edition=fundamental","pubTime":"2026-04-09 09:38","pubTimestamp":1775698699,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) rose more than 5% during morning trading. At the time of writing, the stock was up 4.55% to HK$37.2, with a turnover of HK$5.53 million. The increase follows an announcement from...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","09939","02595","BK4588","BK1574","VXUS","BK4585","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626979113","title":"BRIEF-Genfleet Therapeutics (Shanghai) Says GFH375 Granted Breakthrough Therapy Designation By China's NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2626979113","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626979113?lang=en_us&edition=fundamental","pubTime":"2026-04-09 09:19","pubTimestamp":1775697597,"startTime":"0","endTime":"0","summary":"BRIEF-Genfleet Therapeutics (Shanghai) Says GFH375 Granted Breakthrough Therapy Designation By China's NMPAApril 9 (Reuters) - GenFleet Therapeutics (Shanghai) Inc 2595.HK:GFH375 GRANTED BREAKTHROUGH ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40R1FM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166167640","title":"GENFLEET-B's GFH375 Granted Second Breakthrough Therapy Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1166167640","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166167640?lang=en_us&edition=fundamental","pubTime":"2026-04-09 08:14","pubTimestamp":1775693673,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) announced that its oral KRAS G12D (ON/OFF) inhibitor, GFH375, has been included in the Breakthrough Therapy Designation (BTD) list by the Center for Drug Evaluation of the National...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09939","BK1574","02595","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626975327","title":"GenFleet says China grants breakthrough designation for GFH375 in metastatic pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2626975327","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626975327?lang=en_us&edition=fundamental","pubTime":"2026-04-09 08:00","pubTimestamp":1775692848,"startTime":"0","endTime":"0","summary":"GenFleet KRAS G12D inhibitor GFH375 won Breakthrough Therapy Designation from China drug regulator for monotherapy in KRAS G12D-mutant metastatic pancreatic cancer patients who received at least one prior systemic therapy.Designation marks first China BTD listing for KRAS G12D inhibitor monotherapy in pancreatic cancer.GenFleet said GFH375 entered phase III registrational study in 2025 across about 40 clinical sites in China.Partner Verastem began ex-China development in 2025 under name VS-7375.Verastem’s VS-7375 also received US FDA Fast Track status for KRAS G12D-mutant pancreatic ductal adenocarcinoma.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics  Inc. published the original content used to generate this news","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL5m3rYP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","VSTM","BK4139","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626755829","title":"Genfleet Therapeutics (Shanghai) Inc - Gfh375 Granted Breakthrough Therapy Designation by China's National Medical Products Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2626755829","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626755829?lang=en_us&edition=fundamental","pubTime":"2026-04-09 08:00","pubTimestamp":1775692847,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40R1FM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625629489","title":"3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 46.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625629489","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625629489?lang=en_us&edition=fundamental","pubTime":"2026-04-06 06:04","pubTimestamp":1775426660,"startTime":"0","endTime":"0","summary":"Amidst ongoing geopolitical tensions and energy market volatility, Asian markets have displayed mixed performance, with investors navigating both regional challenges and opportunities. In this environment, identifying undervalued stocks can be a strategic approach for investors seeking potential value plays, especially when these stocks are trading at significant discounts relative to their intrinsic worth.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2595/genfleet-therapeutics-shanghai-shares/news/3-asian-stocks-estimated-to-be-trading-at-discounts-of-up-to-32","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2595/genfleet-therapeutics-shanghai-shares/news/3-asian-stocks-estimated-to-be-trading-at-discounts-of-up-to-32","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK8007","02595","BK1161","VGL.NZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176661857","title":"Wellington Management Increases Stake in GENFLEET-B by Approximately 318,247 Shares at Average Price of HK$30.88","url":"https://stock-news.laohu8.com/highlight/detail?id=1176661857","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176661857?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:32","pubTimestamp":1774870347,"startTime":"0","endTime":"0","summary":"On March 26, Wellington Management Group LLP purchased an additional 318,247 shares of GENFLEET-B (02595) at an average price of HK$30.8754 per share, according to the latest data from the Hong Kong...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02595","EWH","BK1515","159938","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622891431","title":"GenFleet Therapeutics SEHK 2595 Deepens Losses As Revenue Growth Tests Bullish Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2622891431","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622891431?lang=en_us&edition=fundamental","pubTime":"2026-03-27 03:05","pubTimestamp":1774551916,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics (Shanghai) (SEHK:2595) has just released its FY 2025 figures, with first half revenue at C¥88.7 million and basic EPS at a loss of C¥27.02 per share, setting the tone for a period where margins remain firmly in loss-making territory. The company has seen first half revenue move from C¥0 in 2024 to C¥88.7 million in 2025, while basic EPS shifted from a loss of C¥18.02 to a deeper loss of C¥27.02. This puts the spotlight on how quickly revenue can scale against persistent...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2595/genfleet-therapeutics-shanghai-shares/news/genfleet-therapeutics-sehk-2595-deepens-losses-as-revenue-gr","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2595/genfleet-therapeutics-shanghai-shares/news/genfleet-therapeutics-sehk-2595-deepens-losses-as-revenue-gr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02595","BLSG","BK4539","BK4139","BLSX","BK1161","BK4112","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132923572","title":"CLSA Raises Target Price for GENFLEET-B to HK$61.9, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1132923572","media":"Stock News","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132923572?lang=en_us&edition=fundamental","pubTime":"2026-03-26 11:17","pubTimestamp":1774495045,"startTime":"0","endTime":"0","summary":"CLSA released a research report indicating that GENFLEET-B (02595) reported revenue of RMB 130 million last year, a year-on-year increase of 24.42%. R&D expenses were RMB 282 million, down 15.01%...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","159938","09939","BK1161","BK1574","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136203088","title":"Stock Track | GENFLEET-B Soars 5.34% Intraday as Key Drug Added to China's National Reimbursement List","url":"https://stock-news.laohu8.com/highlight/detail?id=1136203088","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136203088?lang=en_us&edition=fundamental","pubTime":"2026-03-25 10:00","pubTimestamp":1774404047,"startTime":"0","endTime":"0","summary":"Shares of GENFLEET-B (02595) surged 5.34% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.The sharp increase appears to be driven by the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622048809","title":"BRIEF-Genfleet Therapeutics (Shanghai) Posts FY Loss RMB1.79 BLN","url":"https://stock-news.laohu8.com/highlight/detail?id=2622048809","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622048809?lang=en_us&edition=fundamental","pubTime":"2026-03-25 09:49","pubTimestamp":1774403390,"startTime":"0","endTime":"0","summary":"BRIEF-Genfleet Therapeutics (Shanghai) Posts FY Loss RMB1.79 BLNMarch 25 (Reuters) - GenFleet Therapeutics (Shanghai) Inc 2595.HK:FY REVENUE RMB130.3 MILLIONFY LOSS RMB1.79 BILLIONFurther company coverage: 2595.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40C16L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180994017","title":"GENFLEET-B Announces Appointment of Huang Meifeng as Co-Company Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=1180994017","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180994017?lang=en_us&edition=fundamental","pubTime":"2026-03-25 07:55","pubTimestamp":1774396530,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) has announced that Wu Dongcheng has resigned from his positions as Co-Company Secretary, Authorized Representative, and Agent for Service of Legal Process, effective March 24,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","159938","02595","BK1574","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109216060","title":"GENFLEET-B Reports Annual Loss Widening to 17.95 Billion Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1109216060","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109216060?lang=en_us&edition=fundamental","pubTime":"2026-03-25 07:54","pubTimestamp":1774396463,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) announced its annual results for the period ending December 31, 2025. The company reported revenue of 130 million yuan, representing a year-on-year increase of 24.42%. Research and...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","02595","09939","BK1574","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193863533","title":"GenFleet Therapeutics FY 2025: Revenue Climbs 24% While Fair-Value Charges Deepen Net Loss; Cash Reserves Surpass RMB 2.07 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1193863533","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193863533?lang=en_us&edition=fundamental","pubTime":"2026-03-25 07:41","pubTimestamp":1774395716,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics (Shanghai) Inc. released FY 2025 results showing revenue of RMB 130.27 million, a 24.45% increase from RMB 104.70 million in 2024. Growth was driven primarily by licensing...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123632597","title":"GenFleet Therapeutics Updates Audit Committee Charter to Strengthen Governance Framework","url":"https://stock-news.laohu8.com/highlight/detail?id=1123632597","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123632597?lang=en_us&edition=fundamental","pubTime":"2026-03-25 07:41","pubTimestamp":1774395705,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics (Shanghai) Inc. released a revised version of its Audit Committee Terms of Reference, adopted on 24 March 2026, aiming to fortify board-level oversight, enhance transparency and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622011274","title":"Genfleet Therapeutics (Shanghai) Inc - FY Loss RMB1.79 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2622011274","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622011274?lang=en_us&edition=fundamental","pubTime":"2026-03-25 07:32","pubTimestamp":1774395139,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C16L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622011788","title":"GenFleet FY2025 net loss widens to RMB 1.79 billion as revenue rises 24.41% to RMB 130 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622011788","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622011788?lang=en_us&edition=fundamental","pubTime":"2026-03-25 07:31","pubTimestamp":1774395095,"startTime":"0","endTime":"0","summary":"GenFleet published an annual results announcement for the year ended Dec. 31, 2025.Revenue rose 24.42% to RMB130.3 million, driven primarily by the GFH375 collaboration and out-licensing arrangement with Verastem.Loss for the year was RMB1.8 billion, while adjusted loss  narrowed 9.3% to RMB226.5 million.Research and development costs fell 15.01% to RMB282.3 million, mainly due to lower termination and patent licensing fees recorded in 2024.Cash and bank balances were RMB2.1 billion as of Dec. 31, 2025, and management said it expects to generate more operating cash flow through commercialization of fulzerasib and additional third-party collaborations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics  Inc. published ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL8wv7nJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK4139","BK1161","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622001120","title":"Genfleet KRAS G12C inhibitor fulzerasib added to China’s national drug reimbursement list","url":"https://stock-news.laohu8.com/highlight/detail?id=2622001120","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622001120?lang=en_us&edition=fundamental","pubTime":"2026-03-25 07:31","pubTimestamp":1774395082,"startTime":"0","endTime":"0","summary":"Genfleet reported that its KRAS G12C inhibitor fulzerasib became the company’s first marketed product in mainland China and was later approved for sale in Macau.The company said fulzerasib was added to China’s national reimbursement drug list, with coverage scheduled to take effect in 2026.Genfleet stated that it is also advancing multiple RAS-targeted programs, including a KRAS G12D candidate that it expects to support broader pipeline partnering and future commercialization planning.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 24, 2026, and is solel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL9VqqrB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02595"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":73,"code":"91000000","status":"200"}]}}